WCLC 2026: Lung cancer research highlights
WCLC 2026: Lung cancer research highlights
Izalontamab brenitecan shows promising activity in previously treated EGFR mutated NSCLC
Multilevel factors shaping blinatumomab delivery across diverse LMICs
Building the cancer system of the future in UAE
Zidesamtinib shows promising efficacy in TKI-naïve ROS1-positive advanced NSCLC
Isa-VRd shows sustained benefit in transplant-ineligible newly diagnosed multiple myeloma
Pembrolizumab plus chemotherapy shows pathological responses in resectable pleural mesothelioma
Adjuvant osimertinib delivers sustained long term survival benefit in EGFR mutated NSCLC
Cemiplimab shows strong survival benefit in KRAS G12C positive advanced NSCLC
Amivantamab plus chemotherapy extends overall survival in EGFR exon 20 insertion NSCLC
Biomarker guided PARP inhibitor maintenance improves outcomes in ovarian cancer meta analysis of phase 3 trials
Prolgolimab plus chemotherapy improves long term survival in advanced nonsquamous NSCLC